AUTHORS
Hooda Said, MS, Theerapat Phoka, PhD2, Grace Dudek3, Matteo Colleoni, MD4, Stefano Rivella, PhD5, Laura Breda, PhD6, Mohamad-Gabriel Alameh, PhD7
AFFILIATIONS
1 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
2 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
3 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
4 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
5 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
6 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
7 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
ABSTRACT
Messenger RNA-lipid nanoparticles (mRNA-LNPs) have emerged as a transformative platform for in vivo gene expression, enabling clinical advances spanning prophylactic vaccines to protein replacement therapies. Despite this progress, the biological principles governing LNP performance have been largely defined in healthy preclinical systems. Systemic diseases characterized by chronic inflammation, oxidative stress, vascular dysfunction, and multi-organ pathology, such as hemoglobinopathies, present a fundamentally altered physiological landscape that may impact LNP biodistribution, cellular uptake, and intracellular RNA processing. It remains unclear whether LNP behavior observed in healthy systems can be extrapolated to disease contexts, or whether disease-specific factors produce qualitatively distinct delivery and expression profiles that would hinder the translational robustness of current paradigms. Here, using the Townes mouse model of sickle cell disease (SCD), we demonstrate that pathophysiology reprograms the in vivo performance of mRNA-LNPs.
To determine the impact of disease severity on functional mRNA delivery, firefly luciferase (FLuc) mRNA-LNPs were intravenously administered to healthy (A/A) and SCD (S/S) Townes mice. Ex vivo bioluminescence imaging of the whole body and major organs showed an inverse relationship with disease severity, whereby S/S mice exhibited an 80% reduction in FLuc expression compared to A/A mice. While expression was diminished in the liver and other vital organs, S/S mice consistently demonstrated a >150% increase in lung expression, revealing a disease-specific redistribution of mRNA.
To investigate whether the altered expression profile was driven, in part, by circulating factors, FLuc mRNA-LNPs were incubated in serum derived from wild-type and homozygous sickle cell mice prior to administration into wild-type Balb/c recipients. Dynamic light scattering and nanoparticle tracking analysis confirmed that serum incubation did not alter LNP size or particle concentration. Despite preserved particle integrity, preexposure to S/S serum of FLuc mRNA-LNPs reduced hepatic FLuc expression in healthy mice by >50% relative to healthy serum, indicating that circulating components present in the SCD serum milieu are sufficient to impair functional mRNA expression in otherwise healthy mice. In contrast, the increased pulmonary expression observed in S/S mice was not reproduced by serum transfer alone, suggesting that additional disease-associated physiological changes contribute to the altered tropism observed.
These results demonstrate that LNPs exhibit reduced functional expression of mRNA in homozygous sickle mice while undergoing a redistribution of organ-specific activity. Ongoing studies are investigating how disease-associated nano-bio interactions contribute to altered LNP performance. Collectively, these findings establish physiological state as a critical determinant of mRNA-LNP performance and highlight the necessity of evaluating delivery systems within disease-relevant biological contexts, where systemic, cellular, and organ alterations can affect their bioavailability and therefore reshape therapeutic outcomes.
DISCLOSURES
Hooda Said, MS: No relevant conflicts of interest to declare.